Using gentamicin to prevent catheter infections
Official title: A Randomized Controlled Trial to Evaluate the Effectiveness of Gentamicin Bladder Instillation on CAUTI
Run by St. Joseph's Hospital and Medical Center, Phoenix · NCT06332040 · Data updated 2026-11-12
This study is testing if using gentamicin to wash out the bladder can help prevent urinary tract infections in hospitalized patients with catheters.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | St. Joseph's Hospital and Medical Center, Phoenix Academic / other |
| Locations | 1 site (Phoenix, Arizona) |
| Status | Recruiting |
| Started | October 9, 2023 |
| Main results expected | October 8, 2026 |
| Study ends | October 8, 2026 |
| Registry record updated | July 11, 2025 |
| Trial ID | NCT06332040 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who are admitted with trauma, surgical, or neuro-critical care diagnoses and have an indwelling Foley catheter.
✕Probably not a fit
Patients with recent urinary infections, traumatic bladder injuries, or allergies to gentamicin will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of prophylactic gentamicin bladder irrigation in preventing catheter-associated urinary tract infections (CAUTIs) in hospitalized patients. It is a prospective randomized controlled trial that will involve patients over 18 years old who have an indwelling Foley catheter due to trauma, surgical, or neuro-critical care conditions. The study seeks to address the high incidence of CAUTIs, which are considered preventable but still occur frequently despite existing prevention strategies. By testing this intervention, the trial hopes to provide a new approach to reducing CAUTI rates in critical care settings.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of CAUTIs, leading to better patient outcomes and lower healthcare costs.
How similar studies have gone: While there have been various approaches to preventing CAUTIs, the specific use of gentamicin bladder irrigation in this context is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age greater than 18 2. admitted with a trauma, surgical, or neuro-critical care diagnosis 3. indwelling foley catheter in place Exclusion Criteria: 1. Documented positive UA or Urine Culture within the past 7 days or upon admission 2. Traumatic bladder injury 3. Gross hematuria 4. Chronic indwelling urethral or chronic suprapubic foley catheter 5. allergy to gentamicin or similar aminoglycosides
Where it's running
-
St. Jpseph's Hospital and Medical Center
Phoenix, Arizona, United States Recruiting
Study contacts
- Principal investigator: Hahn Soe-Lin, MD — St. Joseph's Hospital and Medical Center, Phoenix
- Study coordinator: Kristina M Kupanoff, PhD
- Email: Kristina.Kupanoff@commonspirit.org
- Phone: 602-406-5192
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Irrisept to reduce urinary tract infections when a urethral catheter is removed
This study tests whether rinsing the bladder with Irrisept (0.05% chlorhexidine) instead of saline at the time of catheter removal reduces UTIs in adults having their urethral catheter removed.
-
New device to improve intravenous therapy safety
This study is testing a new device that aims to make intravenous treatments safer and more effective for patients by reducing risks like infections and catheter problems.
-
BGB-58067 in MTAP-deleted glioblastoma (newly diagnosed)
This study tests BGB-58067 in adults with newly diagnosed GBM that show MTAP deletion to see how the drug behaves in the body, how it affects tumor biology, and whether it is safe.
-
B7-H3 targeted antibody-drug conjugate (risvutatug rezetecan) for recurrent Grade 4 glioma and brain metastases
This study will try risvutatug rezetecan, a B7-H3 antibody-drug conjugate, in adults with recurrent Grade 4 glioma or brain metastases who are undergoing surgical resection.
-
Testing BMS-986504 in patients with recurrent glioblastoma
This study is testing a new drug called BMS-986504 in patients with recurrent glioblastoma who have a specific genetic change to see if it is safe and how well it works before surgery.
-
Memory training program for people with early memory problems
This study is testing if a memory training program can help people with early memory problems feel better and improve their memory while also looking at a blood marker related to Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.